Leadership

Michel Detheux, PhD

Independent Chair of the Board

Michel Detheux currently serves as President, and Chief Executive Officer of iTeos Therapeutics. He co-founded iTeos and led the company from its preclinical origins to late-stage clinical development, financially raising nearly $1 billion in 2020-2021 through a NASDAQ IPO and one of the largest upfront strategic deals ever for an early-stage asset with GlaxoSmithKline to co-develop and co-commercialize belrestotug, iTeos’ differentiated anti-TIGIT antibody. Prior to founding iTeos, he served as a Director at Ludwig Cancer Research. Dr. Detheux began his career at Ogeda (f/k/a Euroscreen) where he worked in various scientific and business development roles.